MIM
IPSC icon

Monashee Investment Management’s Century Therapeutics IPSC Stock Holding History

Monashee Investment Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-60,000
Closed -$1.76M – 317
2021
Q2 		$1.76M Buy
+60,000
New +$1.52M 0.21% 140

Other funds holding IPSC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Monashee Investment Management's IPSC Position: Q3 2021 in Review

Monashee Investment Management sold out of Century Therapeutics (IPSC) in Q3 2021, closing a stake of 60,000 shares — an estimated $1.76M sold.

Monashee Investment Management first reported a position in IPSC in Q2 2021 and held it in 1 quarter. The position peaked at $1.76M in Q2 2021. 49 funds tracked by Wall St. Rank hold IPSC as of Q3 2021.

  • Monashee Investment Management reported no remaining Century Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Monashee Investment Management sold 60,000 Century Therapeutics shares in Q3 2021, an estimated $1.76M.
  • Monashee Investment Management first reported a position in Century Therapeutics in Q2 2021 and held it in 1 quarter.
  • Monashee Investment Management's Century Therapeutics position peaked at $1.76M in Q2 2021.
  • 49 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2021.

Based on Monashee Investment Management's 13F filing for Q3 2021, filed 9 Nov 2021.